Graduation Year

2025

Document Type

Thesis

Degree

M.S.

Degree Name

Master of Science (M.S.)

Degree Granting Department

Pharmacy

Major Professor

Diane S. Allen-Gipson, Ph.D.

Committee Member

Bill J. Baker, Ph.D.

Committee Member

Mark Kindy, Ph.D.

Keywords

Green Synthesis, Inflammation, AgNP’s, Lung Injury, Marigold (Calendula officinalis), Oxidative Stress, Silver Nanoparticles

Abstract

Chronic respiratory diseases (CRDs) and other lung conditions are a key cause of the problems facing global health, as they greatly increase morbidity, death, and the financial burden. In order to achieve the third Sustainable Development Goal of the United Nations, which is to reduce premature mortality from non-communicable illnesses by one-third by 2030, updated epidemiological statistics are crucial for directing prevention, control, and treatment measures. One of the major reasons of illness and death globally is chronic obstructive pulmonary disease (COPD). Lung damage and the emergence of CRDs, such as asthma, emphysema, COPD, and other respiratory disorders, are largely caused by inflammation and oxidative stress. There is an urgent need for innovative approaches because traditional therapeutic approaches are frequently constrained, ineffective, and have adverse effects.Examining marigold (Calendula officinalis) conjugated silver nanoparticles (Marigold-AgNPs) as a possible lung damage treatment method is the aim of this study. During the green, plant-mediated synthesis of the nanoparticles, marigold extract was utilized as a stabilizing and reducing agent, incorporating advantageous phytochemicals directly into the nanoparticle structure. Nanoparticle formation, size, shape, surface charge, and colloidal stability were all confirmed by thorough characterization using Ultraviolet-Visible spectroscopy Plate Reader, Transmission Electron Microscopy (TEM), and Zeta Potential Analysis. Marigold-AgNPs should be well absorbed by lung cells, lowering inflammation and oxidative stress while promoting cell health. It is anticipated that this versatile nanotechnology platform will become a safe and biocompatible approach to treating lung disorders, including chronic respiratory conditions. Preclinical in vivo studies, targeted delivery system optimization, long-term safety assessments, and translational research should be given top priority in future studies in order to progress therapeutic clinical applications. In general, this strategy seeks to combine nanotechnology with bioactive compounds that are naturally occurring in order to create novel, long-lasting, and efficient treatments for lung conditions all over the world.

Download

Share

COinS